Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.

Huilin TangStephen E KimmelSteven M SmithKenneth CusiWeilong ShiMatthew J GurkaAlmut G WintersteinSerena Jingchuan Guo

Published in: Diabetes care (2022)

There appear to be comparable cardiorenal benefits of SGLT2 inhibitors and GLP-1RAs between Asian and White participants enrolled in CV and renal outcome trials; the two therapies seem to have similar CV benefits for Asian participants.

Keyphrases

wild type
double blind
clinical trial
randomized controlled trial
placebo controlled